Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroTech Medical (Hangzhou) Co., Ltd.
微泰醫療器械(杭州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2235)

(1) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ABOLITION OF THE SUPERVISORY COMMITTEE; (2) PROPOSED ELECTION OF DIRECTORS (OTHER THAN INDEPENDENT NON-EXECUTIVE DIRECTORS) OF THE THIRD SESSION OF THE BOARD; AND (3) PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE THIRD SESSION OF THE BOARD

I. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ABOLITION OF THE SUPERVISORY COMMITTEE

The proposed amendments (the "**Proposed Amendments**") to the existing articles of association (the "**Articles of Association**") of MicroTech Medical (Hangzhou) Co., Ltd. (the "**Company**") are primarily related to the abolition of the supervisory committee of the Company (the "**Supervisory Committee**") in accordance with the relevant provisions of the Company Law of the People's Republic of China (the "**Company Law**"), and its powers shall be exercised by the audit committee of the board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") accordingly. Meanwhile, the Articles of Association will be updated accordingly in accordance with the latest regulatory requirements of the Company Law and other relevant laws and regulations, and with reference to the corporate governance-related provisions set out in the Guidelines for Articles of Association of Listed Companies. The full version of the Proposed Amendments will be set out in the circular, which will be despatched to the shareholders of the Company (the "**Shareholders**") in due course. The Board is of the view that the Proposed Amendments are in the overall interests of the Company and the Shareholders. Prior to the Proposed Amendments being considered and approved by the Shareholders, the Supervisory Committee will continue to perform its duties in strict compliance with the relevant laws and regulations and the provisions of the Articles of Association, so as to safeguard the interests of the Company and the Shareholders.

The amended Articles of Association will become effective upon approval of the Proposed Amendments at the extraordinary general meeting of the Company (the "**EGM**") to be convened on December 2, 2026, at which the relevant resolution will be considered and, if thought fit, approved by the Shareholders. Prior to that, the existing Articles of Association shall remain effective.

Upon the Proposed Amendments taking effect, the Company will continue to comply with Appendix A1 to the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**"), meet the core shareholder protection standards through compliance with PRC laws together with its Articles of Association, and further monitor its ongoing compliance with these rules. Upon the Proposed Amendments to the Articles of Association taking effect, the Company will no longer establish the Supervisory Committee, and the Rules of Procedure for the Supervisory Committee and other systems related to the Supervisory Committee shall be abolished simultaneously.

II. PROPOSED ELECTION OF DIRECTORS (OTHER THAN INDEPENDENT NON-EXECUTIVE DIRECTORS) OF THE THIRD SESSION OF THE BOARD

Given the expiry of the term of office of the Directors of the second session of the Board, the Board convened a meeting on the date of this announcement to propose the election of the Directors (other than independent non-executive Directors) of the third session of the Board.

The Board proposes to elect Dr. Zheng Pan and Dr. Shi Yonghui as the executive Directors of the third session of the Board, and to elect Mr. Mao Shuo and Ms. Gao Yun as the non-executive Directors of the third session of the Board, and authorize the Board to fix their remuneration. Biographical details of the candidates are set out in Appendix I to this announcement.

The Company convened the employee representatives' meeting on October 27, 2026 to elect Dr. Yu Fei as the employee representative director of the Company, who will form the Company's third session of the Board, together with the Directors to be elected at the EGM.

The nomination committee of the Company (the "**Nomination Committee**"), having reviewed the composition of the Board and assessed the backgrounds and experiences of Dr. Zheng Pan, Dr. Shi Yonghui, Mr. Mao Shuo and Ms. Gao Yun, recommends that Dr. Zheng Pan and Dr. Shi Yonghui be elected as the executive Directors, and Mr. Mao Shuo and Ms. Gao Yun be elected as the non-executive Directors at the EGM in accordance with the nomination policy and board diversity policy of the Company (including but not limited to gender, age, cultural and educational background, ethnicity, geographical location, professional experience, skills, knowledge and length of service). In view of their extensive knowledge and invaluable experience, the Board accepts the nomination by the Nomination Committee and it considers that their election is in the best interests of the Company and all Shareholders as a whole.

Ms. Liu Xiu, an executive Director of the second session of the Board, has informed the Board that she will not seek re-election as an executive Director, in order to devote more time to the Company's finance and risk control management and other related matters. Ms. Liu Xiu will cease to be an executive Director of the Company with effect from the date of election of the third session of the Board at the EGM and will continue to serve as the financial controller of the Company. To the best of the Board's knowledge and belief, having made all reasonable enquiries, Ms. Liu Xiu has confirmed to the Board that there is no disagreement between her and the Board and that she is not aware of any matter that needs to be brought to the attention of the Shareholders in relation to her not seeking re-election as an executive Director.

Dr. Yu Fei, an executive Director of the second session of the Board, has informed the Board that he will not seek re-election as an executive Director given the fact that he has been elected as the employee representative director of the Company on October 27, 2026. Dr. Yu Fei will cease to be an executive Director of the Company with effect from the date of election of the third session of the Board at the EGM. To the best of the Board's knowledge and belief, having made all reasonable enquiries, Dr. Yu Fei has confirmed to the Board that there is no disagreement between him and the Board and that he is not aware of any matter that needs to be brought to the attention of the Shareholders in relation to his not seeking re-election as an executive Director.

Saved as disclosed in this announcement, there are no other matters in relation to proposed election of Directors (other than independent non-executive Directors) that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

III. PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE THIRD SESSION OF THE BOARD

Given the expiry of the term of office of the Directors of the second session of the Board, the Board convened a meeting on the date of this announcement to propose the election of the independent non-executive Directors of the third session of the Board.

The Board proposes to elect Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua as the independent non-executive Directors of the third session of the Board, and authorize the Board to fix their remuneration.

The Nomination Committee, having reviewed the composition of the Board and the Strategy Committee of the Board and having assessed the backgrounds and experiences of Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua, recommends that Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng, and Dr. Cheng Hua be elected as the independent non-executive Directors of the Company at the EGM in accordance with the nomination policy and board diversity policy of the Company (including but not limited to gender, age, cultural and educational background, ethnicity, geographical location, professional experience, skills, knowledge and length of service). Each of Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua has extensive expertise and experience in accounting, smart healthcare and corporate management, and they have confirmed their independence pursuant to Rule 3.13 of the Listing Rules. The Nomination Committee has also assessed and was satisfied with their independence based on the independence criteria as set out in Rule 3.13 of the Listing Rules.

In view of the extensive knowledge and invaluable experience of Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua, the Board accepts the nomination proposed by the Nomination Committee. Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua will bring a broader perspective to the Board and provide new notions for the Company's overall strategic planning and business development. The Board is of the view that their election is in the best interests of the Company and all Shareholders as a whole. Their biographical details are set out in Appendix I to this announcement.

Saved as disclosed in this announcement, there are no other matters in relation to proposed election of independent non-executive Directors that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

IV. GENERAL

The Company will convene the EGM on December 2, 2026, for the relevant Shareholders to consider and, if thought fit, to approve, among other things, (i) the proposed amendments to the Articles of Association and abolition of the Supervisory Committee; (ii) the proposed election of Directors of the third session of the Board; and (iii) the proposed use of capital reserve to make up for losses. A circular containing, among other things, details of the aforesaid matters, together with the notice of EGM, will be despatched to the Shareholders as soon as practicable in accordance with the requirements under the Listing Rules and the Articles of Association currently in force.

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, November 2, 2026

As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.

APPENDIX I

Biographical details of Director candidates for the third session of the Board are set out below:

Executive Directors

Dr. Zheng Pan (鄭攀), aged 55, is the chairman of our Board, an executive Director and the Chief Executive Officer. Dr. Zheng founded our Company in January 2011 and has been the chairman of the Board since March 2016 and the Chief Executive Officer since January 2011, respectively. He was re-designated as an executive Director of our Company in April 2021. He is primarily responsible for the overall strategic planning, business direction and operational management of our Company.

Dr. Zheng has nearly 20 years of experience in the healthcare industry. Prior to founding our Company, he successively served as a research assistant and a postdoc in Florida State University from 1999 to September 2004 in the United States. From October 2004 to July 2010, Dr. Zheng successively served as a senior mechanical engineer at Centurion Wireless Technologies and a manager at Flextronics San Jose Medical Products Center (美國偉創力聖荷西醫療產品中心), a medical solution provider company.

Dr. Zheng obtained the qualification of professorate senior engineer (教授級高級工程師) from Zhejiang Provincial Department of Human Resources and Social Security (浙江省人力資源和社會保障廳) in July 2012. Dr. Zheng was selected into the first batch of "521" Talents for Global Talents Introduction (杭州市第一批全球引才"521"人才) by Municipal Party Committee Organization Department (Talent Office) (杭州市委人才工作領導小組辦公室) in August 2011, and he won the Innovation Achievement Award of Overseas Returnee Contributions Awards (中國僑界貢獻獎(創新成果)) from All-China Federation of Returned Overseas Chinese in September 2014.

Dr. Zheng received a bachelor's degree from Zhejiang Institute of Technology (浙江工學院) in the PRC with a major in Machine Design and Production Engineering in July 1993, a master's degree from Zhejiang University (浙江大學) in the PRC with a major in Mechanics in March 1996 and a Ph.D. degree with a major in Mechanical Engineering from Florida State University in the United States in August 2004.

As at the date of this announcement, Dr. Zheng is deemed to be interested in 38,700,719 H Shares (representing 22.88% of the total H share capital of the Company) and 71,478,780 domestic Shares (representing 33.69% of the total domestic share capital of the Company).

Dr. Zheng will not receive any remuneration for his appointment as an executive Director from the Company.

Dr. Shi Yonghui (施永輝), aged 46, is an executive Director, the chief strategy & development officer and the senior vice president, the secretary to the Board and the joint company secretary of our Group. Dr. Shi joined our Group in May 2021 and was appointed as our executive Director in June 2021 and the secretary to the Board in August 2022. He was appointed as the joint company secretary on March 27, 2024. He is primarily responsible for and involved in strategic planning, business expansion and corporate development matters of the Group. He is also responsible for information disclosure and organizing Board and Shareholders' meetings.

Prior to joining our Group, Dr. Shi successively served as the research scientist and New Business Development Manager from July 2007 to June 2011 at Procter & Gamble Technology (Beijing) Co., Ltd. (北京寶潔技術有限公司). From July 2013 to May 2021, he successively served as the senior manager and the senior director of Medtronic (Shanghai) Management Co., Ltd. (美敦力(上海)管理有限公司), head of corporate development, venture capital and innovation incubation department of Medtronic Greater China, and member of Medtronic Greater China Management Board, during which time he also served as an investment committee member of Medtronic China Venture Capital Fund, the chairman and general manager of Suzhou Meizhong Venture Capital Management Co., Ltd. (蘇州美眾創業投資管理有限公司), the director of Suzhou Medtronic Sequoia Venture Capital Management Co., Ltd. (蘇州美敦力紅杉創業投資管理有限公司), and the general manager of Shanghai Meiji Entrepreneurship Incubator Management Co., Ltd (上海美濟創業孵化器管理有限公司). Dr. Shi has been serving as the secretary to the Board of the Company since August 2022. He has been serving as an executive Director and the chief strategy & development officer of our Company since June and May 2021, respectively.

Dr. Shi received a bachelor's degree with a major in biochemistry and molecular biology and a Ph.D. degree from Peking University in the PRC in July 2002 and July 2007, respectively. He also obtained a master's degree in business administration from the Wharton School of the University of Pennsylvania in the United States in 2013. Dr. Shi was the co-recipient of the first prize of Natural Science (自然科學一等獎) granted by the Ministry of Education, the PRC in 2009, and he was also recognized as the co-recipient of the second prize of National Natural Science (國家自然科學二等獎) granted by the State Council, the PRC in 2011.

As at the date of this announcement, Dr. Shi is deemed to be interested in 789,400 H Shares (representing 0.47% of the total H share capital of the Company) and 2,123,320 domestic Shares (representing 1.00% of the total domestic share capital of the Company).

Dr. Shi will not receive any remuneration for his appointment as an executive Director from the Company.

Non-executive Directors

Mr. Mao Shuo (毛碩), aged 38, was appointed as a non-executive Director of our Company in December 2023. He is primarily responsible for overseeing Board affairs and giving strategic advice and guidance on the business operation of the Group. He worked as a strategic consultant in the healthcare industry from January 2013 to November 2015 at IQVIA (艾昆緯), a healthcare company. He joined Qiming Venture Partners, a company engaging in venture capital investments, in November 2015 and served as an investment manager, vice president of investment and executive director.

Mr. Mao received a bachelor's degree in biomedical engineering from Tsing Hua University in June 2009, and a master's degree in technology entrepreneurship and management and a master's degree in electrical engineering in December 2011 from the University of Rochester.

Mr. Mao will not receive any remuneration for his appointment as a non-executive Director from the Company.

Ms. Gao Yun (高韻), aged 39, has been a Director of our Company since May 2020. Ms. Gao joined our Group in May 2020 and was re-designated as our non-executive Director in April 2021. She is primarily responsible for overseeing Board affairs and giving strategic advice and guidance on the business operation of the Group.

Between August 2011 and January 2014, Ms. Gao served successively as an analyst and then senior analyst in IMS Health. In February 2014, she joined the Medtronic PLC. (美國美敦力公司), a medical technology company, as the specialist in the Strategy and Business Development Department for a certain period of time. After that, Ms. Gao also worked at SBCVC (HK) Ltd. (軟銀中國資本有限公司) as the investment manager. She has been successively serving as the investment manager, the senior investment manager, the vice president and executive director at Lilly Asia Ventures (禮來亞洲基金), an investment fund since October 2018.

Ms. Gao received a bachelor's degree in medicine from Fudan University in the PRC in June 2011 and a master's degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in December 2016.

Ms. Gao will not receive any remuneration for her appointment as a non-executive Director from the Company.

Independent Non-executive Directors

Dr. Li Lihua (厲力華), aged 61, was appointed as an independent Director of the Company in October 2020 and re-designated as an independent non-executive Director in April 2021. His main responsibility is to participate in the decision making of major events of the Company and to provide advice on corporate governance, audit and remuneration and evaluation of Directors, Supervisors and senior management.

Dr. Li served as an assistant professor and associate professor at the University of South Florida School of Medicine from 1994 to 2006. Since June 2006, He has served as the director of The Institute of Biomedical Engineering and Instrument, the Dean of the School of Life Information and Instrument Engineering, and the Dean of the Institute of Intelligent Health of Hangzhou Dianzi University (杭州電子科技大學).

Dr. Li is well-known in the field of science. In December 2006, he was selected as the first level of "The New Century 151 Talent Project" (新世紀151人才工程) of Zhejiang Province. In August 2006, he was appointed as "Qianjiang Scholar" Distinguished Professor of Zhejiang Higher Education Institution (浙江省高等學校 "錢江學者" 特聘教授). In September 2007, he was awarded the National Science Fund for Outstanding Young Scholars by the National Natural Science Foundation of China (國家自然科學基金委員會). In 2009, he was selected as the national talent of "New Century Millions of Talents Project". Dr. Li was a member of the Science and Technology Development Advisory Committee of Zhejiang Province (浙江省科技發展諮詢委員會委員), a member of the Academic Advisory Committee of Zhijiang Laboratory (之江實驗室學術諮詢委員會), and he is currently a director of the Chinese Society of Biomedical Engineering (中國生物醫學工程學會), the chairman of the Image Information and Control Professional Committee (圖像信息與控制專業委員會), a director of the Chinese Society of Image and Graphics (中國圖象圖形學會) and the chairman of the Medical Imaging Professional Committee (醫學影像專業委員會). Dr. Li plays a leading role in several programs, such as the Key Program under the National Natural Science Foundation of China, the Key Program of Joint Fund for Regional Innovation under the National Natural Science Foundation of China, the Key International Collaboration Program under the National Natural Science Foundation of China, and the Special Program for Strategic Science and Technology Innovation cooperation under China's National Key R&D Programs.

Dr. Li received his ph. D. degree in Signal and Information Processing from Southeast University (東南大學) in China in November 1990.

Dr. Li will receive RMB100,000 per annum as allowance for his service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Mr. Ho Kin Cheong Kelvin (何建昌), aged 59, was appointed as an independent non-executive Director on April 21, 2021. He is primarily responsible for participating in the decision making for our Company's significant events and advising on issues relating to corporate governance, audit and the remuneration and assessment of our Directors, Supervisors and senior management.

Mr. Ho has over 20 years of experience in finance and accounting, company secretary, initial public offering and debt restructuring areas. Mr. Ho worked at Grand Orient Holdings Limited (偉東集團有限公司) (stock code: 0106.HK) from June 1999 to October 2000, serving as the company secretary and chief financial officer. From December 2000 to November 2003, he worked for Hanny Magnetics Limited, a subsidiary of Hanny Holdings Limited (錦興集團有限公司) (currently known as Master Glory Group Limited) (stock code: 0275.HK) at which his last position was financial analyst. From January 2004 to September 2005, he worked for Friedmann Pacific Greater China Investments Limited (富泰大中華投資有限公司) (stock code: 1226.HK) as the company secretary and chief financial officer. From August 2006 to August 2008, he worked for Anhui Tianda Oil Pipes Company Limited (安徽天大石油管材有限公司) (stock code: 0839. HK) as company secretary and chief financial officer. From August 2008 to January 2010, he worked for FU JI Food and Catering Services Holdings Limited (福記食品服務控股有限公司) (currently known as Fresh Express Delivery Holdings Group Co., Limited) (stock code: 1175.HK) as company secretary and chief financial officer. From April 2010 to March 2012 and from May 2012 to December 2014, he worked for Greens Holdings Limited (格菱控股有限公司) (stock code: 1318.HK) at which his last position was company secretary and chief financial officer. From January 2016 to December 2017, he worked for Sand River Golf Club Limited (沙河高爾夫球會有限公司) as the company secretary and chief financial officer. From March 2019 to May 2020, he worked for Richly Field China Development Limited (裕田中國發展有限公司) (stock code: 0313.HK) as the company secretary and chief financial officer. From August 2020 to January 2022, Mr. Ho has been the company secretary and chief financial officer of China Wood International Holding Co., Limited (中木國際控股有限公司) (stock code: 1822.HK).

Mr. Ho was an independent non-executive director of Cheung Tai Hong Holdings Limited (currently known as ITC Properties Group Limited) (祥泰行集團有限公司) (stock code: 0199.HK) from October 2001 to May 2003 and a non-executive director of HongDa Financial Holding Limited (弘達金融控股有限公司) (currently known as China Wood International Holding Co., Limited) (stock code: 1822.HK) from April 2016 to April 2017. From August 2018 to February 2022, Mr. Ho has been an independent non-executive director of CECEP COSTIN New Materials Group Limited (In Provisional Liquidation) (中國節能海東青新材料集團有限公司) ("**CECEP COSTIN**") (stock code: 2228.HK). Based on published information, CECEP COSTIN received a winding up petition and a summons for the appointment of joint provisional liquidators dated October 2017. Mr. Ho's appointment was made subsequent to the winding up petition against CECEP COSTIN and he was appointed by the joint provisional liquidators to meet the relevant requirements

under the Listing Rules. In February 2022, The listing status of CECEP COSTIN was cancelled by the Hong Kong Stock Exchange. From July 2020 to November 2022, Mr. Ho was an independent non-executive director of Rosan Resources Holdings Limited (融信資源控股有限公司) (stock code: 0578.HK). Since August 2020, he has been an independent non-executive director of Green Leader Holdings Group Limited (綠領控股集團有限公司) (stock code: 0061.HK). Since October 2020, he has been an independent non-executive director of Yadong Group Holdings Limited (亞東集團控股有限公司) (stock code: 1795.HK) and JW (Cayman) Therapeutics Co. Ltd (藥明巨諾(開曼)有限公司) (stock code: 2126.HK).

Notwithstanding the above appointments as independent non-executive director, Mr. Ho confirmed that he will devote sufficient time to act as an independent non-executive Director of our Company. In addition, Mr. Ho acting as independent non-executive director is neither a full-time member of the above-mentioned listed companies nor involved in day-to-day operations or management of the above-mentioned listed companies, and as such he has no executive or management responsibility.

Mr. Ho was admitted as an associate member of the Hong Kong Institute of Certified Public Accountants in June 1997 and a fellow member of The Association of Chartered Certified Accountants in the United Kingdom in April 2002. He has passed the Securities Broker Examination of The Stock Exchange of Hong Kong Limited in March 2000. Mr. Ho obtained a bachelor degree of business administration from Hong Kong Baptist College (currently known as Hong Kong Baptist University) in Hong Kong in November 1990.

Mr. Ho will receive HK$220,000 per annum as allowance for his service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Ms. Wang Chunfeng (王春鳳), aged 44, was appointed as an independent Director of our Company in October 2020 and re-designated as an independent non-executive Director in April 2021. She is primarily responsible for participating in the decision making for our Company's significant events and advising on issues relating to corporate governance, audit and the remuneration and assessment of our Directors, Supervisors and senior management.

Ms. Wang served successively as the supervisor, securities affairs representative and the director of the administrative management center of Enjoyor Co., Ltd. (銀江股份有限公司), whose shares are listed on the Shenzhen Stock Exchange (stock code: 300020) from September 2007 to July 2010. Since 2010, she has been working at Yinjiang Incubator Co., Ltd. (銀江孵化器股份有限公司) where she previously served as the chief executive officer and the vice chairperson and she currently serves as the director of Yinchuangxiang Entrepreneurship Services Co., Ltd. (銀創享創業服務股份有限公司) and the president of Zhejiang Yinjiang Entrepreneurship Service Research Institute Co., Ltd (浙江銀江創業服務研究院有限公司).

Ms. Wang received a master's degree in business administration from Lanzhou University of Technology (蘭州理工大學) in the PRC in December 2015. She was granted the third prize of Hangzhou Science and Technology Progress Award (杭州市科技進步三等獎) by Hangzhou Science and Technology Bureau (杭州市科學技術局) in October 2011.

Ms. Wang will receive RMB100,000 per annum as allowance for her service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to her qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Dr. Cheng Hua (程華), aged 62, was appointed as an independent non-executive Director of our Company in December 2022. Her main responsibility is to participate in the decision making of major events of the Company and to provide advice on corporate governance, audit and remuneration and evaluation of Directors, Supervisors and senior management.

Dr. Cheng acted as the deputy director of Institute of Science and Technology, Zhejiang Sci-Tech University from November 2005 to November 2016, the director of School of Economics and Management, Zhejiang Sci-Tech University from December 2016 to December 2020, and an instructor of Department of Business Management, Zhejiang Sci-Tech University from October 2020 to May 2026. She has been working as an independent director of Zhejiang Xingxing Refrigeration Co., Ltd. from October 2020 to October 2026.

Dr. Cheng was awarded a bachelor's degree in management engineering in July 1986 by Donghua University (formerly known as China Textile University), a master's degree in business management in March 1992 by Shanghai University of Finance and Economics, and a doctoral degree in agricultural economics and management in March 2004 by School of Management, Zhejiang University.

Dr. Cheng will receive RMB100,000 per annum as allowance for her service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to her qualifications, experience, duties and responsibilities, and the prevailing market conditions.

Employee Representative Director

Dr. Yu Fei (于非), aged 44, is an executive Director and the Chief Technology Officer of our Company. Dr. Yu joined our Group in July 2016 and was re-designated as our executive Director in April 2021. He is primarily responsible for the formulation of product development plans and management of R&D matters in respect of technology, project management and intellectual properties.

Prior to joining our Group, Dr. Yu served as a senior biomedical engineer in the Diabetes Division of Medtronic PLC. (美國美敦力公司), a medical technology company, from May 2013 to July 2016, where he was responsible for researching, developing, deploying and validating new electrochemical biosensor system. Dr. Yu served as the R&D director of the Company from August 2016 to December 2024. He has been serving as a Director and Chief Technology Officer of the Company since October 2020 and December 2024, respectively.

Dr. Yu received a bachelor's degree in Bioengineering from National University of Singapore in Singapore on June 30, 2007 and a Ph.D. degree in biomedical engineering from University of Southern California in the United States in May 2013. Dr. Yu was recognized as an overseas high-level talent in Zhejiang Province in April 2020.

As at the date of this announcement, Dr. Yu is deemed to be interested in 211,000 H Shares (representing 0.12% of the total H share capital of the Company) and 2,269,008 domestic Shares (representing 1.07% of the total domestic share capital of the Company).

Dr. Yu will not receive any remuneration for his appointment as an employee representative Director from the Company.

If the above-mentioned candidates are appointed as Directors, they will each enter into a service contract with the Company and serve until the expiration of the third session of the Board for a term of three years.

Saved as disclosed above, as at the date of this announcement, each Director proposed to be elected (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years, or other major appointments and professional qualifications; (ii) was not related to any Directors, Supervisors, senior management or substantial Shareholders of the Company; (iii) was not interested in any Shares within the meaning of Part XV of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong); and (iv) did not hold any other position with the Company or other members of the Group.